Table 3.
Clinical ongoing trials in ACC.
| Subtype | Target | Drug | Study type | Status | ClinicalTrials identifier |
|---|---|---|---|---|---|
| All histologies | c-MET | Cabozantinib | Phase II | Active, not recruiting | NCT03729297 |
| All histologies | PD-1 | Nivolumab | Phase II | Active, not recruiting | NCT03132038 |
| All histologies | PD-1 CTLA-4 | Nivolumab + ipilimumab | Phase II | Active, not recruiting | NCT03146650 |
| All histologies | PD-1 | Pembrolizumab | Phase II | Recruiting | NCT02628067 |
| All histologies | PD-1 CTLA-4 | Nivolumab + ipilimumab | Phase II | Recruiting | NCT02834013 |
| All histologies | PD-1 VEGFR | Pembrolizumab + lenvatinib | Phase II | Not yet recruiting | NCT04209660 |
| All histologies | PSMA | Lutetium-177 PSMA | Phase II | Not yet recruiting | NCT04291300 |
| Adenoid cystic only | VEGFR PD-L1 | Axitinib + avelumab | Phase II | Recruiting | NCT03990571 |
| Adenoid cystic carcinoma + other tumors | NOTCH | CB-103 | Phase I/II | Recruiting | NCT03422679 |
| All histologies + other tumors | NOTCH | BBI503 (amcarsetinib) | Phase Ib/II | Active, not recruiting | NCT01781455 |
| Adenoid cystic only | NOTCH | AL 101 | Phase II | Recruiting | NCT03691207 |
| Solid tumors | MYB | TeTMYB + BGBA17 | Phase I | Not yet recruiting | NCT03287427 |